Devers Shannon L. 4

4 · IONIS PHARMACEUTICALS INC · Filed Mar 5, 2026

Insider Transaction Report

Form 4

Period: 2026-03-03

IONIS PHARMACEUTICALS INCIONS

Devers Shannon L.

EVP, Chief Human Resources Ofc

Transactions

Exercise/Conversion
Common Stock
2026-03-03$37.58/sh+3,510$131,906→ 26,051 total
Exercise/Conversion
Common Stock
2026-03-03$40.85/sh+3,760$153,596→ 29,811 total
Exercise/Conversion
Common Stock
2026-03-03$34.69/sh+5,500$190,795→ 35,311 total
Exercise/Conversion
Common Stock
2026-03-03$32.60/sh+6,951$226,603→ 42,262 total
Exercise/Conversion
Common Stock
2026-03-03$52.87/sh+385$20,355→ 42,647 total
Sale
Common Stock
[F1][F2]
2026-03-03$79.11/sh−14,321$1,133,006→ 28,326 total
Sale
Common Stock
[F1][F3]
2026-03-03$80.00/sh−5,030$402,395→ 23,296 total
Sale
Common Stock
[F1][F4]
2026-03-03$80.84/sh−755$61,032→ 22,541 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−6,951→ 928 total
Exercise: $32.60From: 2023-01-03Exp: 2032-01-02→ Common Stock (6,951 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−5,500→ 16,500 total
Exercise: $34.69From: 2026-01-02Exp: 2035-01-01→ Common Stock (5,500 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−3,510→ 5,744 total
Exercise: $37.58From: 2024-01-03Exp: 2033-01-02→ Common Stock (3,510 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−3,760→ 11,280 total
Exercise: $40.85From: 2025-09-29Exp: 2034-09-28→ Common Stock (3,760 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−385→ 8,877 total
Exercise: $52.87From: 2020-01-02Exp: 2034-01-01→ Common Stock (385 underlying)

Footnotes (4)

[F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.61 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.68 to $80.675 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers|2026-03-05

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT